{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:01:56Z","timestamp":1791414116433,"version":"4.3.3"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":1888,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, some patients remain at high risk for an unfavorable treatment outcome. The endTB Observational Study is the largest multicountry cohort of patients with rifampin-resistant TB or MDR-TB treated in routine care with delamanid- and\/or bedaquiline-containing regimens according to World Health Organization guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We report the frequency of sputum culture conversion within 6 months of treatment initiation and the risk factors for nonconversion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included patients with a positive baseline culture who initiated a first endTB regimen before April 2018. Two consecutive negative cultures collected 15 days or more apart constituted culture conversion. We used generalized mixed models to derive marginal predictions for the probability of culture conversion in key subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>A total of 1,109 patients initiated a multidrug treatment containing bedaquiline (63%), delamanid (27%), or both (10%). Of these, 939 (85%) experienced culture conversion within 6 months. In adjusted analyses, patients with HIV had a lower probability of conversion (0.73; 95% confidence interval [CI], 0.62\u20130.84) than patients without HIV (0.84; 95% CI, 0.79\u20130.90; P\u2009=\u20090.03). Patients with both cavitary disease and highly positive sputum smear had a lower probability of conversion (0.68; 95% CI, 0.57\u20130.79) relative to patients without either (0.89; 95% CI, 0.84\u20130.95; P\u2009=\u20090.0004). Hepatitis C infection, diabetes mellitus or glucose intolerance, and baseline resistance were not associated with conversion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Frequent sputum conversion in patients with rifampin-resistant TB or MDR-TB who were treated with bedaquiline and\/or delamanid underscores the need for urgent expanded access to these drugs. There is a need to optimize treatment for patients with HIV and extensive disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202001-0135oc","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T14:41:23Z","timestamp":1595601683000},"page":"111-119","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":50,"title":["Culture Conversion in Patients Treated with Bedaquiline and\/or Delamanid. A Prospective Multicountry Study"],"prefix":"10.1093","volume":"203","author":[{"given":"Molly F.","family":"Franke","sequence":"first","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Partners In Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palwasha","family":"Khan","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Hewison","sequence":"additional","affiliation":[{"name":"Medical Department, Doctors Without Borders, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzma","family":"Khan","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Huerga","sequence":"additional","affiliation":[{"name":"Field Epidemiology Department, Epicentre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwonjune J.","family":"Seung","sequence":"additional","affiliation":[{"name":"Partners In Health, Boston, Massachusetts"},{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Rich","sequence":"additional","affiliation":[{"name":"Partners In Health, Boston, Massachusetts"},{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khin","family":"Zarli","sequence":"additional","affiliation":[{"name":"Medical Department, Doctors Without Borders, Yangon, Myanmar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazgul","family":"Samieva","sequence":"additional","affiliation":[{"name":"Medical Department, Doctors Without Borders, Bishkek, Kyrgyzstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Oyewusi","sequence":"additional","affiliation":[{"name":"Partners In Health, Maseru, Lesotho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvati","family":"Nair","sequence":"additional","affiliation":[{"name":"Medical Department, Doctors Without Borders, Minsk, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaz","family":"Mudassar","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nara","family":"Melikyan","sequence":"additional","affiliation":[{"name":"Field Epidemiology Department, Epicentre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putri","family":"Lenggogeni","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Lecca","sequence":"additional","affiliation":[{"name":"Partners In Health, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andargachew","family":"Kumsa","sequence":"additional","affiliation":[{"name":"Partners In Health, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira","family":"Khan","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirajul","family":"Islam","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerow","family":"Hussein","sequence":"additional","affiliation":[{"name":"Medical Department, Doctors Without Borders, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisny","family":"Docteur","sequence":"additional","affiliation":[{"name":"Partners In Health, Cange, Haiti"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Chumburidze","sequence":"additional","affiliation":[{"name":"Medical Department, Doctors Without Borders, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmira","family":"Berikova","sequence":"additional","affiliation":[{"name":"Partners In Health, Astana, Kazakhstan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakob","family":"Atshemyan","sequence":"additional","affiliation":[{"name":"Medical Department, Doctors Without Borders, Yerevan, Armenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Atwood","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manzurul","family":"Alam","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Interactive Research and Development, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Bastard","sequence":"additional","affiliation":[{"name":"Field Epidemiology Department, Epicentre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole D.","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Partners In Health, Boston, Massachusetts"},{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"key":"2026030322035594800_bib1","article-title":"Global tuberculosis report 2019","author":"World Health Organization","year":"2019 [ 2020  28]"},{"key":"2026030322035594800_bib2","article-title":"Global tuberculosis report 2018","author":"World Health Organization","year":"2018 [ 2020  28]"},{"key":"2026030322035594800_bib3","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/tmi.12146","article-title":"\u2018I cry every day\u2019: experiences of patients co-infected with HIV and multidrug-resistant tuberculosis","volume":"18","author":"Isaakidis","year":"2013","journal-title":"Trop Med Int Health"},{"key":"2026030322035594800_bib4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/1471-2334-14-542","article-title":"Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss","volume":"14","author":"Modongo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2026030322035594800_bib5","doi-asserted-by":"crossref","first-page":"e02586-16","DOI":"10.1128\/AAC.02586-16","article-title":"Adverse effects and choice between the injectable Agents amikacin and capreomycin in multidrug-resistant tuberculosis","volume":"61","author":"Arnold","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030322035594800_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40360-015-0036-7","article-title":"Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort","volume":"16","author":"Sagwa","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026030322035594800_bib7","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.5588\/ijtld.17.0468","article-title":"The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?","volume":"21","author":"Reuter","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030322035594800_bib8","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"2026030322035594800_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"2026030322035594800_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030322035594800_bib11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3201\/eid2505.181823","article-title":"Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis","volume":"25","author":"Mbuagbaw","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2026030322035594800_bib12","doi-asserted-by":"crossref","first-page":"1900811","DOI":"10.1183\/13993003.00811-2019","article-title":"Final treatment outcomes of delamanid-containing regimens in patients with MDR-\/XDR-TB in South Korea","volume":"54","author":"Mok","year":"2019","journal-title":"Eur Respir J"},{"key":"2026030322035594800_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026030322035594800_bib14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026030322035594800_bib15","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030322035594800_bib16","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00125812","article-title":"Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis","volume":"41","author":"Skripconoka","year":"2013","journal-title":"Eur Respir J"},{"key":"2026030322035594800_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1415332","article-title":"Delamanid for extensively drug-resistant tuberculosis","volume":"373","author":"Gupta","year":"2015","journal-title":"N Engl J Med"},{"key":"2026030322035594800_bib18","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1183\/09031936.00176314","article-title":"Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid","volume":"45","author":"Wells","year":"2015","journal-title":"Eur Respir J"},{"key":"2026030322035594800_bib19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1164\/rccm.201801-0019LE","article-title":"Bedaquiline and repurposed drugs for fluoroquinolone-resistant multidrug-resistant tuberculosis: how much better are they?","volume":"198","author":"Bastard","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030322035594800_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/cid\/ciz1084","article-title":"Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis","volume":"71","author":"Seung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026030322035594800_bib21","article-title":"Consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019 [ 2020  28]"},{"key":"2026030322035594800_bib22","article-title":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis interim policy guidance","author":"World Health Organization","year":"2013 [ 2020  28]"},{"key":"2026030322035594800_bib23","article-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis interim policy guidance","author":"World Health Organization","year":"2014 [ 2020  28]"},{"key":"2026030322035594800_bib24","doi-asserted-by":"crossref","first-page":"1600803","DOI":"10.1183\/13993003.00803-2016","article-title":"An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis","volume":"49","author":"Bastos","year":"2017","journal-title":"Eur Respir J"},{"key":"2026030322035594800_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.5588\/ijtld.18.0433","article-title":"The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis","volume":"23","author":"Huangfu","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030322035594800_bib26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.5588\/ijtld.10.0352","article-title":"A systematic review of risk factors for death in adults during and after tuberculosis treatment","volume":"15","author":"Waitt","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030322035594800_bib27","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1086\/518665","article-title":"HIV infection and multidrug-resistant tuberculosis: the perfect storm","volume":"196","author":"Wells","year":"2007","journal-title":"J Infect Dis"},{"key":"2026030322035594800_bib28","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug\u2013induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030322035594800_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcma.2017.10.002","article-title":"The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis","volume":"81","author":"Chang","year":"2018","journal-title":"J Chin Med Assoc"},{"key":"2026030322035594800_bib30","first-page":"e83892","article-title":"Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis","volume-title":"PLoS One","author":"Lomtadze","year":"2013"},{"key":"2026030322035594800_bib31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12879-019-4378-4","article-title":"The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens","volume":"19","author":"Khan","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2026030322035594800_bib32","article-title":"endTB Consortium. endTB clinical and programmatic guide for patient management with new TB drugs. Version 4.0","year":"2018"},{"key":"2026030322035594800_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","article-title":"Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies","volume":"3","author":"Kurbatova","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026030322035594800_bib34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-144-9-200605020-00008","article-title":"Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome","volume":"144","author":"Holtz","year":"2006","journal-title":"Ann Intern Med"},{"key":"2026030322035594800_bib35","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat Med"},{"key":"2026030322035594800_bib36","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ije\/dyu029","article-title":"Estimating predicted probabilities from logistic regression: different methods correspond to different target populations","volume":"43","author":"Muller","year":"2014","journal-title":"Int J Epidemiol"},{"key":"2026030322035594800_bib37","doi-asserted-by":"crossref","first-page":"1702467","DOI":"10.1183\/13993003.02467-2017","article-title":"Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea","volume":"51","author":"Kim","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030322035594800_bib38","first-page":"1295","article-title":"Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata","volume":"14","author":"Chamie","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030322035594800_bib39","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1164\/rccm.201312-2140OC","article-title":"Xpert MTB\/RIF as a measure of sputum bacillary burden: variation by HIV status and immunosuppression","volume":"189","author":"Hanrahan","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030322035594800_bib40","first-page":"165","article-title":"Impact of tuberculosis on HIV-1 replication, diversity, and disease progression","volume":"4","author":"Collins","year":"2002","journal-title":"AIDS Rev"},{"key":"2026030322035594800_bib41","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/S2352-3018(19)30035-9","article-title":"Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection","volume":"6","author":"O\u2019Donnell","year":"2019","journal-title":"Lancet HIV"},{"key":"2026030322035594800_bib42","article-title":"Update of Recommendations on first-and second-line antiretroviral regimens","author":"World Health Organization","year":"2019"},{"key":"2026030322035594800_bib43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12879-016-1344-2","article-title":"Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026030322035594800_bib44","article-title":"Hepatitis C key facts","author":"World Health Organization","year":"2019 [ 2020  28]"},{"key":"2026030322035594800_bib45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bmj.316.7136.989","article-title":"When can odds ratios mislead?","volume":"316","author":"Davies","year":"1998","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1164\/rccm.v206erratum2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000}},{"DOI":"10.1164\/rccm.v203erratum6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000}}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/203\/1\/111\/67163504\/ajrccm_203_1_111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/203\/1\/111\/67163504\/ajrccm_203_1_111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T03:05:30Z","timestamp":1772593530000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/203\/1\/111\/8491069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,1]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202001-0135oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"2020-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}